BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, April 3, 2026
Home
»
Newsletters
» BioWorld
BioWorld
April 21, 2005
View Archived Issues
DOR's OrBec For Treating iGVHD Now On NDA Track
Despite missing the primary endpoint in a pivotal trial for orBec to treat intestinal graft-vs.-host disease (iGVHD), DOR BioPharma Inc. intends to file a new drug application before the end of the year. (BioWorld Today)
Read More
Coley's IPO Seeking $115M To Expand Work With TLRs
Read More
Arguments Heard In Supreme Court On Early Research IP
Read More
Molecular Insight Raises $28M In Series C For Imaging Product
Read More
Corgentech Cuts Staff To Slow Spending After E2F Decoy Miss
Read More
With RA Product In Phase II, Merrimack Brings In $28.3M
Read More
Other News To Note
Read More
